Ibrahim, M.; Illa-Bochaca, I.; Fa’ak, F.; Monson, K.R.; Ferguson, R.; Lyu, C.; Vega-Saenz de Miera, E.; Johannet, P.; Chou, M.; Mastroianni, J.;
et al. Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. Cancers 2024, 16, 18.
https://doi.org/10.3390/cancers16010018
AMA Style
Ibrahim M, Illa-Bochaca I, Fa’ak F, Monson KR, Ferguson R, Lyu C, Vega-Saenz de Miera E, Johannet P, Chou M, Mastroianni J,
et al. Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. Cancers. 2024; 16(1):18.
https://doi.org/10.3390/cancers16010018
Chicago/Turabian Style
Ibrahim, Milad, Irineu Illa-Bochaca, Faisal Fa’ak, Kelsey R. Monson, Robert Ferguson, Chen Lyu, Eleazar Vega-Saenz de Miera, Paul Johannet, Margaret Chou, Justin Mastroianni,
and et al. 2024. "Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes" Cancers 16, no. 1: 18.
https://doi.org/10.3390/cancers16010018
APA Style
Ibrahim, M., Illa-Bochaca, I., Fa’ak, F., Monson, K. R., Ferguson, R., Lyu, C., Vega-Saenz de Miera, E., Johannet, P., Chou, M., Mastroianni, J., Darvishian, F., Kirchhoff, T., Zhong, J., Krogsgaard, M., & Osman, I.
(2024). Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. Cancers, 16(1), 18.
https://doi.org/10.3390/cancers16010018
